目的 调查围手术期非甾体抗炎药(nonsteroidal anti-inflammatory drugs,NSAIDs)的临床应用情况,为合理选择及使用此类药物提供参考。方法 本项目为一项多中心、回顾性研究,包括3个部分:①通过问卷调研各机构NSAIDs的临床应用概况;②由疼痛专科临床药师组成专家组,经过多次讨论对药物评价标准形成共识;③随机抽查2016年第4季度至2017年第1季度围手术期使用NSAIDs的病例,严格按照点评标准对药物使用合理性进行评价。结果 本项目在16家综合性三级医院开展,共抽查病例960份。其中,NSAIDs为15家(93.8%)机构围手术期常用的镇痛药物,使用金额排序前3位的NSAIDs依次为氟比洛芬酯注射液、注射用帕瑞昔布钠及塞来昔布胶囊。10家(62.5%)机构未常规干预NSAIDs的不合理使用,仅有2家(12.5%)机构制定了NSAIDs使用规范。抽查病例的总体不合理率为23.3%(n=224),存在的主要问题为超疗程使用及NSAIDs联用,分别涉及10家医院98例病例(10.2%)及11家医院76例病例(7.9%)。其他问题为:26例病例(2.7%)超禁忌症使用药物,24例病例(2.5%)给药方式不正确。结论 NSAIDs在围手术期使用广泛,但面临使用规范缺失、临床干预不足及不合理使用现象较多的问题。因此,需及时采用措施,推进药学工作介入,规范临床用药。
Abstract
OBJECTIVE To evaluate the appropriateness of nonsteroidal anti-inflammatory drugs (NSAIDs) used in the perioperative period. METHODS This was a retrospective multicenter study with three stages: ①characterization of the application of NSAIDs through questionnaires; ②establishment of an expert group and development of the standard for prescription evaluation; ③random enrollment of cases using NSAIDs during the perioperative period from October 2016 to March 2017 and evaluation of prescriptions. RESULTS The study was conducted in 16 tertiary-care hospitals and included 960 cases. NSAIDs were commonly used in 15 hospitals (93.8%) during the perioperative period. Flurbiprofen axetil injection, parecoxib sodium injection and celecoxib capsule were NSAIDS with the top three expenses. Ten (62.5%) hospitals did not routinely intervene for the irrational use of NSAIDs, and only two (12.5%) hospitals established the regulatory regime of NSAIDs.The overall irrational rate was 23.3% (n=224). Too long continuous medication duration and inappropriate combination of NSAIDs were the main problems, involving 98 cases (10.2%) in 10 hospitals and 76 cases (7.9%) in 11 hospitals, respectively. Other problems were: 26 cases (2.7%) used drugs beyond contraindication, and 24 cases (2.5%) administrated drugs in irrational route.CONCLUSION NSAIDs are widely used in the perioperative period. Lack of regulatory regime, insufficient clinical intervention and irrational prescriptions are the current status of NSAIDs usage. Therefore, it is necessary to take powerful measures and effective pharmaceutical intervention to improve the use of NSAIDs.
关键词
围手术期 /
非甾体抗炎药 /
合理用药 /
多中心研究
{{custom_keyword}} /
Key words
perioperative period /
non-steroidal anti-inflammatory drug /
rational drug use /
multicenter research
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SCHMIDT M, LAMBERTS M, OLSEN A M, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology [J]. Eur Heart J, 2016, 37(13):1015.
[2] RAO Y F, WANG R R, LU X Y, et al. Progress in the application of non-steroidal anti-inflammatory drugs in perioperative pain management of enhanced recovery of after surgery [J]. Chin J Gen Surg(中华普通外科杂志), 2017, 32(3):282-284.
[3] CHOU R, GORDON D B, DE LEON-CASASOLA O A, et al. Management of postoperative pain: a clinical practice guideline from the american pain society, the american society of regional anesthesia and pain medicine, and the american society of anesthesiologists′ committee on regional anesthesia, executive committee, and administrative council [J]. J Pain, 2016, 17(2):131-157.
[4] CHINESE SOCIETY OF ANESTHESIOLOGY. Expert consensus on pain management after adult surgery [J]. J Clin Anesthesiol(临床麻醉学杂志), 2017, 33(9):911-917.
[5] LIU Z J, CHEN D, LIU C S, et al. Analysis of the application of perioperative analgesics in 100 patients in our hospital [J]. Chin Pharm J(中国药学杂志), 2013, 48(6):492-494.
[6] CHINESE SLE TREATMENT AND RESEARCH GROUP. Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications [J]. Chin J Intern Med(中华内科杂志), 2017, 56(1):81-85.
[7] LENG X S, WEI J M, LIU L X, et al. Expert consensus on perioperative pain management in general surgery[J]. Chin J Gen Surg(中华普通外科杂志), 2015, 30(2):166-173.
[8] LÜ N, KONG Y, MU L, et al. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial [J]. Eur Radiol, 2016, 26(10):3492-3499.
[9] KAY B, PAOLA P. New insights into the use of currently available non-steroidal anti-inflammatory drugs [J]. J Pain Res, 2015, 8:105-118.
[10] CHEN Z, JI L W, XIE X H. Analysis on the rationality of aspirin in inpatients with diabetes [J]. Chin Pharm J(中国药学杂志), 2018, 53(3):234-238.
[11] VOELKER M, SCHACHTEL B P, COOPER S A, et al. Efficacy of disintegrating aspirin in two different models for acute mild-to-moderate pain: sore throat pain and dental pain [J]. Inflammopharmacology, 2016, 24(1):43-51.
[12] CAI H W, XU H M. Use of nonsteroidal anti-inflammatory drug in patients with cardiovascular disease [J]. Chin Pharm J(中国药学杂志), 2014, 49(6):512-516.
[13] Anesthesiology Group for Elderly Patients, Chinese Society of Anesthesiology. Guidance on perioperative anesthesia management for elderly patients in China [J]. Int J Anesth Resu(国际麻醉学与复苏杂志), 2014, 35(12):1057-1069.
[14] SEEMA S, VIVEK M. Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management [J]. Postgrad Med J, 2012, 88(1036):73-78.
[15] YANG P, JIANG S P, LU X Y. Effectiveness of continuous improvement by a clinical pharmacist-led guidance team on the prophylactic antibiotics usage rationality in intervention procedure at a Chinese tertiary teaching hospital [J]. Ther Clin Risk Manag, 2017, 13:469-476.
[16] CHEN J, LU X Y, WANG W J, et al. Impact of a clinical pharmacist-led guidance team on cancer pain therapy in China: a prospective multicenter cohort study [J]. J Pain Symptom Manage, 2014, 48(4):500-509.
[17] ZHU L, WU J Y, GAO Z, et al. Standards of multiple electrolytic and invert sugar injection specific prescription evaluation with analysis of results and clinical improvement [J]. Chin Pharm J(中国药学杂志), 2017, 52(11):986-990.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
浙江省药学会科研专项资助(2017ZYY03)
{{custom_fund}}
PDF(1002 KB)
